As the excitement builds around the FDA’s potential support of psilocybin-based drugs, ketamine-derived medicines have largely flown under the radar, despite securing regulatory approval back in 2019.
Braxia Scientific is one of the organisations championing the psychedelic medicine, with four clinics providing innovative ketamine treatments in Canada. The first Braxia Health Clinic opened in 2018; since then the Canadian centres have administered 3,000 intravenous ketamine infusions and 345 intranasal and sublingual treatments.
The Government of Canada recently awarded the company funding to support a trial into the use of ketamine to treat bipolar disorder, in conjunction with Toronto’s University Health Network. Globally, approximately 46 million people suffer from bipolar disorder, signalling significant opportunities for treatments with high safety and efficacy profiles.
A presenting company at the PSYCH Investor Summit: Research & Development on 7 July, Braxia trades on the CSX as BRAX and on OTC Markets as BRAXF, with the opportunity to provide short-term returns for investors as it develops future formulations.
Although the organisation’s primary focus is running clinics that provide treatments for mental health issues, Braxia has invested in the creation and commercialisation of ketamine-based and psilocybin-based therapies. It has also established a psilocybin-assisted clinical therapy training programme, to train and support medical physicians, with the ambition to become vertically integrated.
Driving these aspirations is Roger McIntyre, Braxia’s acting Chairman and CEO. A Professor of Psychiatry and Pharmacology at the University of Toronto, McIntyre is an expert on mood disorders and has co-edited several textbooks on the subject. A contributor to clinical practice guidelines around the world, he was lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders, and helped create the Canadian Network for Mood and Anxiety Treatments guidelines for depressive disorders.
McIntyre will be speaking at the 7 July PSYCH Investor Summit: Research & Development on a panel discussion regarding industry innovation. He will be joined by Richard Carleton, CEO at Canadian Securities Exchange (CSE), Business Insider journalist Yeji Jesse Lee, and Greg McKee, CEO and Chairman at Tryp Therapeutics.
The Braxia CEO will deliver an investor-focused company presentation, followed by a question-answer session on the company’s ecosystem. The full agenda for the industry-leading summit can be found here. Have you registered to attend the PSYCH Investor Summit: Research & Development? If not, you can secure your ticket here.The post Braxia Scientific Identifies Short-Term ROI in Psychedelic Medicine first appeared on PSYCH. psilocybin ketamine psychiatry psychedelic therapeutics therapy anxiety investors funding cse otc tryp therapeutics tryp braxia scientific braxia fda research